Cargando…
Evaluation of novel protease inhibitors against darunavir‐resistant variants of HIV type 1
HIV disease became a manageable chronic disease since combination antiretroviral therapy (cART) was introduced as the standard treatment regimen. However, the emergence of drug‐resistant viruses is a major problem associated with cART. A phenotypic drug susceptibility test using a lentiviral vector...
Autores principales: | Inoue, Mari, Oyama, Daiki, Hidaka, Koushi, Kameoka, Masanori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5221448/ https://www.ncbi.nlm.nih.gov/pubmed/28097091 http://dx.doi.org/10.1002/2211-5463.12160 |
Ejemplares similares
-
Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021) -
Structures of Darunavir-Resistant HIV-1 Protease
Mutant Reveal Atypical Binding of Darunavir to Wide Open Flaps
por: Zhang, Ying, et al.
Publicado: (2014) -
The HIV protease inhibitor darunavir prevents kidney injury via HIV-independent mechanisms
por: Gao, Xiaobo, et al.
Publicado: (2019) -
Unique Flap Conformation in an HIV-1 Protease with High-Level Darunavir Resistance
por: Nakashima, Masaaki, et al.
Publicado: (2016) -
Protease mutations emerging on darunavir in protease inhibitor-naïve and experienced patients in the UK
por: El Bouzidi, Kate, et al.
Publicado: (2014)